Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuhang Wang

Showing results (181-190 of 183) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 183 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2020
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Ning Li, Shunyu Gao, et al.
The Lancet Regional Health. Western Pacific|November 25, 2022
The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challengesHuiyao Huang, Yu Tang, Yue Yu, et al.
Pageof 19

Showing results (181-190 of 183) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 183 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2020
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Ning Li, Shunyu Gao, et al.
The Lancet Regional Health. Western Pacific|November 25, 2022
The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challengesHuiyao Huang, Yu Tang, Yue Yu, et al.
Pageof 19